Skip to content
Screener

Baxter International BAX Cash & Equivalents

Cash & Equivalents at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$708M-11.3%
Stryker logo
StrykerSYK
$3.39B+42.8%
KORU Medical Systems logo
KORU Medical SystemsKRMD
$8.29M+2.9%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$139M+19.6%
Axogen logo
AxogenAXGN
$96.57M+271%
ICU Medical logo
ICU MedicalICUI
$298.3M-0.6%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$14.66B+22.3%
Enterprise value$12.86B+22.1%
P/S1.3×+0.2×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028962
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other financing activities, net(14)(24)
Cash flows from (used in) financing activities(11)(3,226)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations(18)36
Increase (decrease) in cash, cash equivalents and restricted cash51(118)
Cash, cash equivalents and restricted cash at beginning of period (1)1,9682,414
Cash, cash equivalents and restricted cash at end of period (1)2,0192,296
Less cash and cash equivalents of discontinued operations
Cash, cash equivalents and restricted cash of continuing operations$2,019$2,296

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's cash & equivalents?
Baxter International (BAX) reported cash & equivalents of $2.02B in Q1 2026.
How has Baxter International's cash & equivalents changed year-over-year?
Baxter International's cash & equivalents decreased by 12.1% year-over-year, from $2.3B to $2.02B.
What is the long-term trend for Baxter International's cash & equivalents?
Over 5 years (2020 to 2025), Baxter International's cash & equivalents has grown at a -12.1% compound annual growth rate (CAGR), from $3.74B to $1.97B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Baxter International's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude